Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Adrenocortical Carcinoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Paraganglioma 1Osteosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasm Metastasis 1Insulinoma 1Hepatoblastoma 1Glucagonoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Carcinoma 1Carcinoid Tumor 1

Interventions

Temozolomide 2Capecitabine 2veliparib 1pazopanib 1cixutumumab 1Salts 1Octreotide 1Lansoprazole 1Everolimus 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Zollinger-Ellison Syndrome × cixutumumab × Endocrine × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡